Home
This site is intended for healthcare professionals

Primary Care Obesity Roadmap Australia: Module 3 Plateau or Non-Response?

Share

Description

This activity is supported by an independent education grant from Lilly. This online education program has been designed for healthcare professionals globally, excluding the UK.

Join leading expert Dr. Ralph Audehm for this virtual session exploring the primary care management of obesity treatment plateaus and non-response. Utilizing interactive clinical cases, this expert-led webinar equips healthcare providers with evidence-based strategies to evaluate treatment efficacy, navigate complex therapeutic plateaus during anti-obesity medication therapy, and proactively manage side effects through patient-centric monitoring.

Participants will explore actionable pathways to address clinical hesitation and evaluate patients who fail to reach standard weight-loss targets, such as a 5% reduction at the 12-week or 16-week mark. By reviewing factors like dose optimization, medication adherence, and lifestyle support, practitioners will learn to collaboratively adjust treatment plans rather than prematurely abandoning therapy. Furthermore, the session emphasizes the chronic nature of obesity, providing structured guidance on transitioning patients through therapeutic plateaus while preserving body composition and maximizing long-term health benefits.

This is Module Three of Four. Modules One and Two and Four can be found here.

Prefer to read? see our Key Clinical Summary Here

Session Highlights

  • Evaluating Treatment Efficacy and Plateaus: Master structured reassessment algorithms to determine true therapeutic non-response versus a physiological weight plateau early in anti-obesity therapy.
  • Overcoming Adherence Barriers: Gain tactical insights into identifying and addressing the root causes of sub-therapeutic dosing and medication non-adherence, including delayed dose escalation due to patient anxiety or missed doses.
  • Patient-Centric Side-Effect Mitigation: Implement proactive protocols to monitor, counsel, and manage common GLP-1RA adverse events—such as nausea, vomiting, diarrhea, and lightheadedness—to prevent premature treatment discontinuation.
  • Long-Term Goal Setting and Adaptation: Formulate proactive, long-term adherence pathways through shared decision-making, setting personalized, realistic weight loss targets, and executing timely treatment adjustments, combination therapies, or specialist referrals.

Who Should Watch

This activity is intended for primary care providers, nurse practitioners, physician assistants/associates, pharmacists, and other healthcare providers who care for patients with obesity.

Faculty

Dr Ralph Audehm is a general practitioner who graduated from Melbourne University in 1984 and has worked for over 25 years in general practice. He is experienced in managing all types of patients. He obtained a Diploma from the Royal Australian College of Obstetricians and Gynaecologists in 1987 and is an Honorary Clinical Associate Professor at the Department of General Practice, University of Melbourne. He has had a long-standing interest in the management of chronic conditions in General Practice especially diabetes and heart disease.

Disclosures

Partners for Advancing Clinical Education (Partners) requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. All relevant financial relationships are mitigated according to Partners policies.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated according to Partners policies. Others involved in the planning of this activity have no relevant financial relationships.

Dr Ralph Audehm, faculty for this educational activity, has the following relevant financial relationships: Advisory Board and Consultant for AstraZeneca, Boehringer Ingelheim, Lilly and NovoNordisk.

The MedAll staff, program planners, and reviewers have no relevant financial relationships with ineligible companies to disclose.

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by Partners for Advancing Clinical Education (Partners) and MedAll. Partners is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Education

Partners designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physician Associate Continuing Education

Partners has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.25 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.

Nursing Continuing Professional Development

The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 0.25 ANCC contact hours.

Pharmacy Continuing Education

Partners designates this continuing education activity for 0.25 contact hour(s) (0.25 CEUs) of the Accreditation Council for Pharmacy Education.

Universal Activity Number -JA4008073-9999-26-294-H01-P

Type of Activity: Knowledge

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Fee Information

There is no fee for this educational activity.

This continuing education activity is active starting September 10th 2026, and will expire on August 4th 2027.

Estimated time to complete this activity: 15 Minutes

Learning objectives

  1. Employ bias-aware communication and structured shared decision making (SDM) at the point of diagnosis, utilizing the patient's specific metabolic and mechanical complications to collaboratively set function-based goals for people with obesity, demonstrating correct application in > 75% of post-activity case assessments.

  2. Initiate guideline-concordant treatment plans – integrating pharmacotherapy, structured lifestyle interventions, and surgical referrals – while implementing workflows to monitor physical function and preserve body composition, achieving appropriate treatment decisions in > 75% of simulation scenarios.

  3. Apply structured reassessment algorithms to determine treatment efficacy, true therapeutic non-response amid weight plateaus, and timely treatment escalations in > 70% of longitudinal case exercises.

  4. Formulate proactive long-term adherence pathways — including proactive side-effect mitigation, the timely review of concomitant medications, and a patient-centered review of therapeutic options in > 75% of applied decision activities.

Similar communities

View all

Similar events and on demand videos

Computer generated transcript

Warning!
The following transcript was generated automatically from the content and has not been checked or corrected manually.

Solid. When weight loss slows after starting obesity treatment, what do you usually do first? Reassure and continue unchanged, check adherence to tolerability and dose, intensify lifestyle support, change, escalate medication, refer to specialist care. OK. Well, you know, I would hope that um well we'll we'll do many of those as we go through. So let's talk about another chap, a 52 year old man, BMI 36, um, he's um come back after 16 weeks, he's been doing his lifestyle, um, he's had some anti-obesity therapy. He's lost about 4% of his weight by week eight. Um, but he hasn't had any further weight loss. He has had mild nausea, ah, which has just delayed him escalating his dose, so you can guess that we're, um, using an injectable here, but, um, and he reports taking the treatment most weeks. Now I'm sure many of the GPs here are saying, OK, that's a red flag. His BP and his waist circumference have improved slightly. Um, walking tolerance is unchanged, and of course, doc, why isn't it working, and I'm sure many of you already know the answer to this. But, you know, any intervention that we do, um, there, there'll always be an adaptation and we always see the eventual plateauing of that weight loss, and the question really becomes, um, you know, do, do they actually get down to what their goal was, what their target was, um, I mean, if, if they've managed to get down to their target, fantastic, um. But that doesn't mean we stop of course cos we know what happens when, when that happens, but um, for this chat though, um there are a few things that you start to think about that, you know, may not be that adaptive response. So, We do know all people vary, you know, how they, um, you know, react to some of the medications and you know I've got people who are super responders, you know, on small doses of the GLP ones, and then I've got people who need quite high doses. So every person is different, um, but we do want them to really lose that 5% within that 3 month, um, and he didn't quite make it. And of course his story um gave us quite a lot of hints as to why that was, um. And of course we know that for certain things that we aim for, you know, a greater weight loss, so, um, you know, with uh liver disease, metabolic associated steatotic hepatitis, we want about 10%, um, type two prevention's about 5%, um, we've seen some wonderful changes in atherosclerotic vascular disease, cardiovascular disease, so, you know, we do want, To get people down to the target that we've set, and so you can see that that little paradigm on the right, that little pathway that, you know, if, if it really has been adherent and done all the right things and they haven't lost that, you know, more than 5%, do think about switching therapy. If they have lost more than 5%, it really depends how much more and where they're sitting in terms of what their goals were, um, And you know, but if they still need to lose more, uh think of combination therapy or other medications that maybe more efficacious. So, you know, this is, you know, following up, making sure that they are, are titrating their doses to the maximum tolerated dose, that, you know, they're, they're thinking about the goals that they've set, are they achieving them, you know, look at um how their waist circumference is, check their BMI um make sure they're doing their activity, um, but the treatment persisted, so we know from this chap, from what he was saying that that maybe an issue. And of course part of that was the GI tolerability cos he was having quite a bit of nausea, but think of adherence barriers, um, just because people aren't taking it, you know, it's not because they're being wilful, there's usually a reason behind that, and then of course make care, you know, careful assessment of the nutrition, um, and then what we're going to do is either we're gonna continue or we're going to switch or combine or refer. Hi. So when it comes to monitoring um intervals, um, I, like I say, like to see my patients quite a bit in the 1st 2 months, um, and then I tend to space it out, so either within a week or two of starting something, um, and then, um, depending on how they're going, um, it might be monthly for the next 3 or 4 months, um, and then, you know, it's something that we tend to work on together. And of course setting your weight loss targets, you know, for the person, ah which is in front of you, I mean some of my patients sometimes have very unrealistic goals and I think it's really important to um have a goal in between, um. Reviewing what you're doing, um, whether the initial therapy was appropriate, whether you're going to use something else, uh whether you started with a very low energy diet, and they've struggle sort of to maintain the weight as they've come up, so you then might use one of the anti-obesity agents to help them maintain that weight loss, um, and of course, um, You can use the LEDs with some of our um medications and of course it's great because it does has a lot of the micronutrients in it, and of course that can also help with their calorie control. But again, it's very much working with the person that sits in front of you. So, why is this chap, you know, um, not getting to his weight loss goal? So, um, at this visit, what is the most accurate interpretation of his 4% weight loss and plateau? The plateau confirms that the anti-obesity treatment is not suitable for him. He has not probably not been taking the medication as directed. C, therapy will make no difference with BMI 36, he should be referred for bariatric surgery. It's too soon to tell. Dose adherence and tolerability must be checked. Response can only be assessed after he's been placed on a maximal tolerated dose. Now, You know, the answer is D, but I would also say B, so between um B and D and of course D actually um includes a lot of the component of B as well. Um, so what's the next step? Do we stop treatment because weight loss has plateaued, do we check dose adherence, tolerability and response? Do we leave him alone and get him back again in um at the 16 week mark, refer him for bariatric surgery, or really focus on physical activity? But you know, it's always more than that, so yes, checking his dose adherence, tolerability and response, we know that's what the main issue. So. He confirmed that he delayed um upping the, the dose because of nausea, and he missed doses 1 to 2 times in a month, so he's really getting a subtherapeutic dose, um, and so uh and the main thing that was stopping him of course was that nausea, so he was on a, a weekly GLP-1. And so, um, you know, we can slow down, the up titration, so if someone, when they dose escalate, get a surge in problems, We can always go back down, wait a bit longer and then try again. Of course we'd always talk about, um, you know, his uh nutrition and physical activity, um, paying particular attention to the fact that make sure he's not eating big meals, you know, he's going out and then trying to push, uh as much as he can in and then feeling sick or having very fatty, spicy foods cos we know that will tend to aggravate the nausea. Um Obviously checking the, the things that we're looking for, his metabolic issues, um, his walking tolerance and his own goals, and again, rescheduling. Now for him, if he was having that sort of an issue, I would've seen him again in a month, but again, 2 to 3 months uh would be the uh the longest that I would wait because he's struggling and I know we've gotta capture him while where he is now. We've gotta help him, otherwise he'll just drop the whole lot. OK, so. Everyone will plateau eventually because of that metabolic adaptation, but remem we need to check to make sure that people, um, are using the medication appropriately, whether it be GLP ones or some of our oral medications, we've gotta make sure that, um they've got access to it, um, we, You know, need to reassess um the things that we're looking for, you know, to feedback to our patients, you know, the waist circumference, BP, um how they're going with their function and the goals that um, you know, that they've set. I mean, I often ask patients about their belt size, cos they, they often tell you that their pants are getting, you know, looser, which is always a really.